hotspot -WSS

hotspot

author：comprehensive 2025-09-29 03:40:02 - browse：781

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Hospitals struggle to profit from CAR

WSS

H5N1 communication has been strictly for the birds

Tocagen's brain cancer gene therapy trial continues. Investors worry

Study identifies new proteins linked to dementia risk 25 years later

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Google says AlphaFold 3 can map a vast universe of biomolecules

Texas Department of Public Safety speaks out on migrant abuse allegations

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Use wet bulb globe temperature, not heat index, to protect workers

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Sanofi strikes deal with Novavax, boosting the vaccine maker

Alkermes shareholders re

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Anesthesiologist group: stop taking Ozempic before surgery

Stanford president faces new allegations over 1999 paper

Bright Health sells Medicare Advantage business to Molina

Apple Watch's A

leisure time

Medicare says breakthrough device reimbursement rule to come by summer

Use wet bulb globe temperature, not heat index, to protect workers

Readout LOUD podcast: What to know about H5N1 bird flu

What nurses really want: sufficient staffing for patient care

Judge rejects Trump's request to move Stormy Daniels hush

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

knowledge

entertainment

entertainment

knowledge